TY - JOUR
TI - IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients
AU - Vakrakou, A.G.
AU - Tzanetakos, D.
AU - Evangelopoulos, M.-E.
AU - Fragoulis, G.E.
AU - Kazakou, P.
AU - Lekka, E.
AU - Kafasi, N.
AU - Tzartos, J.S.
AU - Andreadou, E.
AU - Koutsis, G.
AU - Gialafos, E.
AU - Dimitrakopoulos, A.
AU - Zampeli, E.
AU - Rontogianni, D.
AU - Theocharis, S.
AU - Zapanti, E.
AU - Stathopoulos, P.-A.
AU - Anagnostouli, M.
AU - Stefanis, L.
AU - Kilidireas, C.
JO - Journal of Neuroimmunology
PY - 2021
VL - 361
TODO - null
SP - null
PB - Elsevier B.V.
SN - 0165-5728
TODO - 10.1016/j.jneuroim.2021.577759
TODO - alemtuzumab;  autoantibody;  biological marker;  complement;  immunoglobulin G, adult;  blood;  etiology;  female;  Graves disease;  human;  immune reconstitution;  immunology;  lymphocyte count;  male;  multiple sclerosis;  neurologic disease;  retrospective study;  young adult, Adult;  Alemtuzumab;  Autoantibodies;  Autoimmune Diseases of the Nervous System;  Biomarkers;  Complement System Proteins;  Female;  Graves Disease;  Humans;  Immune Reconstitution;  Immunoglobulin G;  Infections;  Lymphocyte Count;  Male;  Multiple Sclerosis, Relapsing-Remitting;  Retrospective Studies;  Young Adult
TODO - We aimed to determine whether Alemtuzumab-induced immune reconstitution affects immunoglobulin and complement levels in the serum of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. IgG4-levels were increased 24-months after treatment initiation compared to baseline levels in twenty-nine patients. Alemtuzumab-treated patients with the highest IgG4-levels were more prone to thyroid-related autoimmune manifestations and specific autoimmune adverse events such as Crohn's disease, Graves' disease, and hemolytic anemia. Compared to baseline, total IgG-levels showed a trend towards reduced levels following two-courses of Alemtuzumab, but no significant change of C3 and/or C4-levels was observed. In conclusion, monitoring of IgG4-levels can serve as a marker for secondary autoimmunity risk in multiple sclerosis patients treated with Alemtuzumab. © 2021 Elsevier B.V.
ER -